Yocca Frank 4
4 · BioXcel Therapeutics, Inc. · Filed Jun 16, 2025
Insider Transaction Report
Form 4
Yocca Frank
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-14+33→ 1,906 total - Exercise/Conversion
Common Stock
2025-06-15+35→ 1,941 total - Exercise/Conversion
Restricted Stock Units
2025-06-14−33→ 196 total→ Common Stock (33 underlying) - Exercise/Conversion
Restricted Stock Units
2025-06-15−35→ 352 total→ Common Stock (35 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F3]On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.